# KIORA PHARMACEUTICALS INC (KPRX) — capital_raise/atm_program [announced]
Source: SEC API (secapi.ai) · situation sit_37b2bf2a59a22be0b1df · retrieved 2026-08-12T06:57:28.766Z

## Overview
Kiora Pharmaceuticals is a clinical-stage biotechnology company developing small-molecule therapies for retinal diseases, including KIO-301 (a molecular photoswitch for retinitis pigmentosa) and KIO-104 (a DHODH inhibitor for retinal inflammation).

Kiora Pharmaceuticals secured a private placement for up to $24.0 million in gross proceeds. The company received $5.0 million upfront, with the remaining proceeds contingent on the exercise of near-term milestone-based warrants. The company noted that if a strategic transaction is completed by early next year, it would satisfy a warrant acceleration milestone provision from this private placement that could provide additional capital upon warrant exercise.

## Terms
- Deal value: $24.0M · Consideration: cash

## Key dates
- Announced 2026-08-07

## Timeline
- 2026-08-07 · 8-K (0001372514-26-000075): 8-K - KIORA PHARMACEUTICALS INC — *Kiora Pharmaceuticals is a clinical-stage biotechnology company developing small-molecule therapies for retinal diseases, including KIO-301 (a molecular photoswitch for retinitis pigmentosa) and KIO-104 (a DHODH inhibitor for retinal inflammation).* Kiora Pharmaceuticals secured a private placement for up to $24.0 million in gross proceeds. The company received $5.0 million upfront, with the remaining proceeds contingent on the exercise of near-term milestone-based warrants. The company noted that if a strategic transaction is completed by early next year, it would satisfy a warrant acceleration milestone provision from this private placement that could provide additional capital upon warrant exercise.
  https://www.sec.gov/Archives/edgar/data/1372514/0001372514-26-000075.txt

## Citations
- 0001372514-26-000075 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000137251426000075